This trial is evaluating whether MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8) will improve 2 primary outcomes and 2 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 90 Days from last dose.
This trial requires 55 total participants across 4 different treatment groups
This trial involves 4 different treatments. MSC-exosomes Delivered Intravenously Every Other Day On An Escalating Dose (8:4:8) is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Our analysis in Wuhan suggests that the virus has become more common and widespread in the area than previously estimated. On this basis, it may be important to monitor the spread of the disease, and to consider a range of potential explanations for its appearance and occurrence.
Covid is not a 'cure' but the disease has an impact on the health and wellbeing of individuals and societies. Current global and national efforts need to focus on maintaining quality of care and reducing the burden of the disease.
The treatment of COVID-19-positive individuals should be based on the severity of the symptoms and the possibility of serious complications. The most common treatment measures are aimed at reducing the symptoms and protecting the respiratory system. The possibility of cure must be kept in mind.
About 13% of New York's adult population were infected by February 24. People are at risk if they are exposed to infected persons. People with known comorbidities are at greater risk of acquiring COVID-19. In terms of age groups, more than 1 in 10 adults and children had been exposed to others with COVID-19 by February 24. In New York City, with its high rate of case transmission and widespread prevalence, most adults have been exposed to others with COVID-19.
Covid-19, commonly referred to as coronavirus (COVID-19), is a viral infection, specifically related to SARS-CoV-2, similar to SARS. The COVID-19 virus was initially identified in Wuhan, China, in December 2019, when SARS-CoV had been previously identified.\n
Intravenous MSC-Exo therapy (1x/m/d (2:4:8) does not improve QOL or survival for patients in this retrospective study. Due to the lack of a safety assessment and the complexity of delivering MSC-Exo therapy as an 'on demand' infusion, the question of if 1x/m/d MSC-Exo therapy is a reasonable option will be revisited in a prospective clinical trial.
In a recent study, findings reveal that in comparison with a placebo treatment, treatment with Msc-Exo after EVD is highly efficient in a rabbit model of severe acute pancreatitis. This suggests that Msc-Exo, as originally applied, could be a new standard of care for acute severe pancreatitis and in particular for a life-threatening EVD by intravenous injection. However, more studies are needed to validate our observations and to clarify the mechanisms driving the amylase-neutralizing and anticancer actions and the effects of Msc-Exo on clinical outcomes and immunomodulation.
[About 2% of all hospitalized patients in Italy acquire the disease during the course of the 2019-20 coronavirus outbreak, resulting in a median of 5 days of systemic corticosteroids use in the ICU (95% CI, 3.-7.7; P = 0.006) and an increased hospital readmission rate at a 1-month follow-up (11.0% vs. 4.4%; P = 0.002)](https://gadgets.ncbi.nlm/pages/genetics/lifebiology/gadgets/drosophila.
Recent findings indicates a strong family clustering of symptomatic HCOV infections, suggesting the possibility of a viral transmission in families, which may be influenced by genetic, behavioural, socioeconomic and genetic factors.
These dosing schemes were well tolerated and safely administered over several months. We conclude that (2:4:8) MSC-Exo dosing is safe and well tolerated in the pre-hospital setting and warrants further investigation to increase the number of patients eligible for this dosing strategy.
Patients who had a positive test for SARS, MERS or BSL, or who had had viral exposure within the span of the last year as well as those who had any exposure to non-physicians were at the highest risk for developing SARS or MERS to COVID-19. This information may help to identify patients most in need of antivirals for the prevention of SARS and MERS infections.